Market Cap (In USD)
70.44 Million
Revenue (In USD)
-
Net Income (In USD)
-15.88 Million
Avg. Volume
13.63 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.297-0.935
- PE
- -
- EPS
- -
- Beta Value
- 1.027
- ISIN
- CA80401L3083
- CUSIP
- -
- CIK
- 1421642
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Francis Gleeson B.B.A. M.B.A
- Employee Count
- -
- Website
- https://satellos.com
- Ipo Date
- 2012-08-03
- Details
- Satellos Bioscience Inc., a regenerative medicine company, develops therapeutics to treat degenerative muscle diseases. Its lead program focuses on the development of oral therapeutic drug to correct muscle stem cell polarity and restore the body's innate muscle repair and regeneration process. The company was incorporated in 2012 and is headquartered in Toronto, Canada.
More Stocks
-
ASMTECASM Technologies Limited
ASMTEC
-
6906Groundhog Inc.
6906
-
5271Pecca Group Berhad
5271
-
HELIFirst Helium Inc.
HELI
-
XPROINDIAXpro India Limited
XPROINDIA
-
CHGCF
-
SDMHF
-
0R2PDeere & Company
0R2P